Parabolan 75 (Trenbolone Hexahydrobenzylcarbonate)

Product Overview & Pharmaceutical Specifications

Parabolan 75 is described in the supplied product information as an oil-based sterile injectable solution containing trenbolone hexahydrobenzylcarbonate.

Product Specifications

• Active Pharmaceutical Ingredient (API): Trenbolone hexahydrobenzylcarbonate
• Strength: 75 mg/ml
• Dosage Form: Injectable, oil-based sterile solution
• Route: Intramuscular injection
• Pack Size: 10 ml
• Packaging: Multiple-dose vial
• CAS Number: 23454-33-3
• Molecular Formula: C26H34O4
• Molecular Mass: 410.54576 g/mol
• Manufacturer: Hilma Biocare
• Market Status: Prescription
• Storage: 15–25°C; protect from light

Pharmacology & Product Information

Pharmacological Class

The supplied documentation describes trenbolone as an anabolic steroid with anabolic and androgenic properties.

Anabolic steroids are synthetic derivatives of testosterone. The supplied information states that their actions can include both anabolic and androgenic effects and that complete separation of these effects has not been achieved.

Mechanism of Action

According to the supplied information, trenbolone binds strongly to the androgen receptor, with its pharmacological activity generally considered to derive from this interaction.

The supplied source also describes possible interactions with glucocorticoid, progesterone and prolactin receptor pathways, while noting uncertainty in some areas of the available literature.

The source states that exogenous anabolic androgens can suppress pituitary gonadotropic function. Endogenous testosterone release may consequently be inhibited through suppression of luteinizing hormone (LH), while higher exposure may suppress spermatogenesis through feedback inhibition of follicle-stimulating hormone (FSH).

Pharmacokinetic Information

The supplied product description states that the ester formulation produces an increase in serum trenbolone levels followed by continued elevation for approximately 7–10 days.

This information is reproduced from the supplied source and has not been independently verified.

Documented Applications

The supplied source lists an indication for male patients involving substantial weight loss or loss of body mass where substantial weight gain and increased musculature are considered necessary for patient health, particularly where caloric intake is limited and other anabolic therapies have failed.

The source states that the physician and patient should consider the risks of therapy against potential benefits.

This indication has not been independently verified against current EU marketing authorizations or clinical guidelines.

Adverse Reactions

The supplied documentation reports the following adverse reactions:

Male:

• Gynecomastia
• Excessive frequency and duration of penile erections
• Oligospermia

Skin and Appendages:

• Hirsutism
• Male-pattern baldness
• Acne

Fluid and Electrolyte Disturbances:

• Sodium retention
• Chloride retention
• Water retention
• Potassium retention
• Calcium retention
• Retention of inorganic phosphates

Gastrointestinal and Hepatic:

• Nausea
• Cholestatic jaundice
• Alterations in liver function tests
• Hepatocellular neoplasms
• Peliosis hepatitis
• Hepatic adenomas
• Nephritis
• Cholestatic hepatitis

Hematologic:

• Suppression of clotting factors II, V, VII and X
• Bleeding in patients receiving anticoagulant therapy

Neurological/Psychiatric:

• Increased libido
• Headache
• Anxiety
• Depression
• Extreme agitation
• Irritability
• Generalized paresthesia
• Severe aggressive behaviour

Other:

• Serum lipid changes
• Hypertension
• Hypercalcaemia
• Oedema
• Priapism
• Potentiation of sleep apnea

Drug Interactions

Patients receiving oral anticoagulant therapy require close monitoring when androgen therapy is initiated or discontinued.

The supplied information states that androgens may alter the metabolism of oral hypoglycaemic agents or change insulin sensitivity.

The source also states that metabolism of cyclosporine may be affected and advises avoiding other hepatotoxic medications.

Contraindications

The supplied source lists the following contraindications:

• Known hypersensitivity to any ingredient
• Known or suspected carcinoma of the breast
• Known or suspected testicular carcinoma
• Known or suspected prostate carcinoma
• Severe heart disease
• Liver disease
• Kidney disease
• History of epilepsy

The supplied documentation states that androgen-containing products should not be used in women because of the risk of virilization and fetal harm.

Precautions

The supplied information states that women, children and elderly males should not use the product.

It also states that trenbolone may increase aggressiveness and cause psychiatric changes. Liver function monitoring is identified because of potential hepatotoxicity.

Androgens may alter serum cholesterol concentrations, requiring caution in patients with a history of myocardial infarction or coronary artery disease.

The source advises discontinuation and medical assessment in the event of psychiatric changes or signs of jaundice.

Patient Monitoring

The supplied source identifies the following monitoring parameters:

• Serum cholesterol
• HDL
• LDL
• Triglycerides
• Haemoglobin
• Haematocrit
• Hepatic function tests, including AST and ALT
• PSA
• Total testosterone
• Free testosterone
• Bioavailable testosterone
• Dihydrotestosterone
• Estradiol
• Progesterone
• Prolactin
• Blood pressure

The supplied information also recommends prostate assessment and PSA evaluation for male patients over 40 before androgen use, with periodic evaluation during therapy.

Presentation

Parabolan 75 mg/ml, 10 ml multiple-dose vial.

Storage

Store in a cool, dry place between 15–25°C. Protect from light.

Scientific & Regulatory References

No PubMed references, DOI references, clinical literature citations or official regulatory documents were supplied with the source material.

The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization or national authorization number was supplied.

Pharmaceutical Terms & Compliance

Important: This information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.

Regulatory requirements and authorization status may differ between EU Member States. No EU-wide authorization claim is made here.